RBC Europe’s Revance Therapeutics, Inc. RVNC Stock Holding History

RBC Europe’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-200	Closed	-$5.51K	–	1162
2017 Q3	$5.51K	Buy	+200	New	+$4.85K	﹤0.01%	935

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NCM

NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RBC Europe's RVNC Position: Q4 2017 in Review

RBC Europe sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2017, closing a stake of 200 shares — an estimated $5.51K sold.

RBC Europe first reported a position in RVNC in Q3 2017 and held it in 1 quarter. The position peaked at $5.51K in Q3 2017. 115 funds tracked by Wall St. Rank hold RVNC as of Q4 2017.

RBC Europe reported no remaining Revance Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
RBC Europe sold 200 Revance Therapeutics, Inc. shares in Q4 2017, an estimated $5.51K.
RBC Europe first reported a position in Revance Therapeutics, Inc. in Q3 2017 and held it in 1 quarter.
RBC Europe's Revance Therapeutics, Inc. position peaked at $5.51K in Q3 2017.
115 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2017.

Based on RBC Europe's 13F filing for Q4 2017, filed 9 Nov 2023.